1 / 9

Colorectal Cancer Screening - Economic Considerations

Colorectal Cancer Screening - Economic Considerations. Terri Green University of Canterbury Presentation for “Future of Cancer Screening in New Zealand”. Auckland, 7 August 2015. Economic considerations. Is it value for money? (Yes, potentially) What are the benefits?

julianp
Télécharger la présentation

Colorectal Cancer Screening - Economic Considerations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Colorectal Cancer Screening -Economic Considerations Terri Green University of Canterbury Presentation for “Future of Cancer Screening in New Zealand”. Auckland, 7 August 2015

  2. Economic considerations • Is it value for money? (Yes, potentially) • What are the benefits? • What are the costs? • Can we achieve the benefits? • Can we afford it? • Are there alternatives?

  3. Fig 3. Biennial FOBTi screening, 50-74 years: Referral and Surveillance colonoscopy 2011-2031(Participation 60%, Positivity 6.4%, 4.8%)Green, Richardson and Parry (NZMJ, 2012)

  4. Can we do it? • 18000 colonoscopies rising to 28000 • Assumes • Participation 60% Compared to 55% for pilot • Positivity 6.4% for initial screen • 4.8% for later screens Compared to 7.5% for pilot

  5. What is the cost of Programme?-estimated at $39 M per year* (Sapere, 2015)(Steady state cost; initial years more costly) Key Determinants of cost: • Participation rate in screening (pilot, 55%) • Positivity rate (pilot, 7.5%) • How programme is delivered: • Use of private sector for colonoscopies • Regional variations (*Range $26M-$50M, Sapere report MOH 2015)

  6. Can we afford “it”? • Depends on other demands on public money …… (Annual CRC treatment costs approx $83M*.) • If it can be delivered it is worthy of consideration • Are there alternatives to address Bowel cancer? E.G. screening by once only Flexible Sigmoidoscopy. (*Sheerin, Green, Sarfati, Cox, NZMJ 2015)

  7. Approx Comparison: Annual volumesFOBTi and Flexible Sigmoidoscopy(60% participation) FOBTi (50-74, every 2 years) Flex sig (one-off, age 55) 60,000 target 36,000 screens 1800* colonoscopies (* 5%, Atkins, Lancet, 2010) • 618,000 target • 371,000 screens • 18,000 colonoscopies

  8. Balancing costs and benefits:- FOBTi , compared to Flex sig • Greater Reduction in CRC incidence√ • Greater Reduction in mortality √ • Higher cost • Lower cost per QALY √ • More adverse events • Higher colonoscopy load

More Related